Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 4/20 | 0.76 |
| ▸ | PLK4 | O00444 | 6/20 | 0.74 |
| ▸ | AURKA | O14965 | 4/20 | 0.65 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.65 |
| ▸ | PLK1 | P53350 | 1/20 | 0.64 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.61 |
| ▸ | JAK2 | O60674 | 5/20 | 0.59 |
| ▸ | JAK3 | P52333 | 3/20 | 0.59 |
| ▸ | CDK4 | P11802 | 2/20 | 0.58 |
| ▸ | CDK2 | P24941 | 2/20 | 0.58 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 2/20 | 0.56 |
| ▸ | CDC7 | O00311 | 1/20 | 0.56 |
| ▸ | CIT | O14578 | 1/20 | 0.56 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.56 |
| ▸ | GAK | O14976 | 1/20 | 0.56 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11340146 | 0.86 | IGF1R (1.00) | IGF1RPLK4AURKAAURKBPLK1 | |
| SCHEMBL23887632 | 0.85 | PLK4 (0.74) | IGF1RPLK4AURKAAURKBPLK1 | |
| SCHEMBL30114937 | 0.85 | PLK4 (0.74) | IGF1RPLK4AURKAAURKBPLK1 | |
| SCHEMBL25222845 | 0.85 | PLK4 (0.74) | IGF1RPLK4AURKAAURKBPLK1 | |
| SCHEMBL11346367 | 0.84 | PLK4 (0.72) | IGF1RPLK4AURKAAURKBPLK1 | |
| SCHEMBL30086502 | 0.83 | PLK4 (0.67) | IGF1RPLK4AURKAAURKBPLK1 | |
| SCHEMBL25269921 | 0.83 | PLK4 (0.67) | IGF1RPLK4AURKAAURKBPLK1 | |
| SCHEMBL14079289 | 0.82 | PLK4 (0.69) | IGF1RPLK4AURKAAURKBPLK1 | |
| SCHEMBL23887678 | 0.82 | PLK4 (0.65) | IGF1RPLK4AURKAAURKBPLK1 | |
| SCHEMBL30086328 | 0.82 | PLK4 (0.65) | IGF1RPLK4AURKAAURKBPLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11673879-B2 | Substituted pyrimidines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11673879-B2 | Substituted pyrimidines and methods of use | ALK, TYMP, ENTPD5 | IGF1R 558/4885PLK4 1890/4885AURKA 905/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.